title: Vessel size imaging (VSI) by robust magnetic resonance (MR) relaxometry: MR-VSI of solid tumors in correlation with immunohistology and intravital microscopy.
abstract: The aim of this study was to evaluate a robust magnetic resonance (MR) vessel size imaging (VSI) method for the noninvasive assessment of mean vessel size in solid tumors in a clinical dose range of ultrasmall superparamagnetic particles of iron oxide (USPIO). Therefore, USPIO-enhanced MR-VSI was performed on DU-4475, MDA-MB-435, and EOMA tumor-bearing mice xenografts with known differences in angiogenic activity and vessel morphology. MR results were compared to vessel sizes determined by immunohistochemistry (anti-CD31) and by intravital microscopy (IVM). MR-VSI revealed significantly different mean vessel sizes between the xenograft models at both USPIO doses (DU-4475: 20.6 ± 4.9 μm; MDA-MB-435: 37.4 ± 8.8 μm; and EOMA: 60.3 ±9.6 μm at 80 μmol/kg; p < .05). Immunohistochemistry revealed lower values for all tumor entities, whereas the size distribution was in line with MR-measurements. IVM corroborated the MR results for DU-4475 and MDA-MB435, but showed similar vessel sizes for MDA-MB-435 and EOMA. Our MR-VSI method allowed a noninvasive estimation of the mean vessel size in mice xenograft solid tumors with variable vascularity using a clinically relevant USPIO dose range.
authors: Thorsten
authors: T
authors: Persigehl
authors: Janine
authors: J
authors: Ring
authors: Tymoteusz
authors: T
authors: Budny
authors: Anke
authors: A
authors: Hahnenkamp
authors: Sandra
authors: S
authors: Stoeppeler
authors: Lawrence H
authors: LH
authors: Schwartz
authors: Hans-Ullrich
authors: HU
authors: Spiegel
authors: Walter
authors: W
authors: Heindel
authors: Stefanie
authors: S
authors: Remmele
authors: Christoph
authors: C
authors: Bremer
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D045744:Cell Line, Tumor; D003911:Dextrans; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007211:Indoles / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging / Q000295:instrumentation / Q000379:methods; D058185:Magnetite Nanoparticles; D051379:Mice; D008819:Mice, Nude; D008853:Microscopy / Q000379:methods; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000098:blood supply* / Q000188:drug therapy; D009389:Neovascularization, Pathologic; D011758:Pyrroles / Q000627:therapeutic use*; D011897:Random Allocation; D000077210:Sunitinib
chemical_list: D020533:Angiogenesis Inhibitors; D003911:Dextrans; D007211:Indoles; D058185:Magnetite Nanoparticles; D011758:Pyrroles; C097921:ferumoxtran-10; D000077210:Sunitinib